Analyzing Biocept (BIOC) and Its Competitors

Biocept (NASDAQ: BIOC) is one of 21 public companies in the “Medical laboratories” industry, but how does it compare to its competitors? We will compare Biocept to similar businesses based on the strength of its valuation, risk, analyst recommendations, dividends, profitability, earnings and institutional ownership.

Analyst Recommendations

How to Become a New Pot Stock Millionaire

This is a breakdown of current ratings and price targets for Biocept and its competitors, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biocept 0 0 2 0 3.00
Biocept Competitors 109 455 531 17 2.41

Biocept presently has a consensus price target of $1.25, indicating a potential upside of 420.83%. As a group, “Medical laboratories” companies have a potential upside of 15.39%. Given Biocept’s stronger consensus rating and higher probable upside, research analysts clearly believe Biocept is more favorable than its competitors.

Insider and Institutional Ownership

8.7% of Biocept shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Medical laboratories” companies are owned by institutional investors. 7.7% of Biocept shares are owned by company insiders. Comparatively, 18.5% of shares of all “Medical laboratories” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Biocept and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Biocept $5.07 million -$21.61 million -0.30
Biocept Competitors $1.13 billion $76.65 million 217.33

Biocept’s competitors have higher revenue and earnings than Biocept. Biocept is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Biocept has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Biocept’s competitors have a beta of 1.23, suggesting that their average stock price is 23% more volatile than the S&P 500.


This table compares Biocept and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biocept -426.48% -374.92% -169.29%
Biocept Competitors -118.65% -181.74% -42.76%


Biocept competitors beat Biocept on 9 of the 13 factors compared.

About Biocept

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients who have been diagnosed with cancer based on molecular drivers. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, and melanoma. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with's FREE daily email newsletter.

Leave a Reply